A Tutorial on Modern Bayesian Methods in Clinical Trials

被引:16
作者
Muehlemann, Natalia [1 ]
Zhou, Tianjian [2 ]
Mukherjee, Rajat [3 ]
Hossain, Munshi Imran [1 ]
Roychoudhury, Satrajit [4 ]
Russek-Cohen, Estelle [5 ]
机构
[1] Cytel, Cambridge, MA 02139 USA
[2] Colorado State Univ, Dept Stat, Ft Collins, CO USA
[3] Alira Hlth, Barcelona, Spain
[4] Pfizer Inc, New York, NY USA
[5] ERCStat, Silver Spring, MD USA
关键词
Bayesian methods; Bayesian statistics; Clinical development; Clinical trials; Drug development; SIZE;
D O I
10.1007/s43441-023-00515-3
中图分类号
R-058 [];
学科分类号
摘要
Clinical trials continue to be the gold standard for evaluating new medical technologies. New advancements in modern computation power have led to increasing interest in Bayesian methods. Despite the multiple benefits of Bayesian approaches, application to clinical trials has been limited. Based on insights from the survey of clinical researchers in drug development conducted by the Drug Information Association Bayesian Scientific Working Group (DIA BSWG), insufficient knowledge of Bayesian approaches was ranked as the most important perceived barrier to implementing Bayesian methods. Results of the same survey indicate that clinical researchers may find the interpretation of results from a Bayesian analysis to be more useful than conventional interpretations. In this article, we illustrate key concepts tied to Bayesian methods, starting with familiar concepts widely used in clinical practice before advancing in complexity, and use practical illustrations from clinical development.
引用
收藏
页码:402 / 416
页数:15
相关论文
共 33 条
  • [1] [Anonymous], 2002, PRIOR DISTRIBUTION
  • [2] [Anonymous], 2020, INT FDA COMPL INN TR
  • [3] [Anonymous], 2019, RAR DIS NAT HIST STU
  • [4] [Anonymous], 2010, GUID US BAYES STAT M
  • [5] [Anonymous], 2020, DEV LIC VACC PREV CO
  • [6] Boyd CE, 2015, AQUACULTURE, RESOURCE USE, AND THE ENVIRONMENT, P1, DOI 10.1002/9781118857915
  • [7] Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers
    Bray, Ross
    Hartley, Andrew
    Wenkert, Deborah
    Muehlemann, Natalia
    Natanegara, Fanni
    Harrell, Frank E.
    Wang, Fei
    Clark, Jennifer
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 426 - 435
  • [8] Not Too Big, Not Too Small: A Goldilocks Approach To Sample Size Selection
    Broglio, Kristine R.
    Connor, Jason T.
    Berry, Scott M.
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (03) : 685 - 705
  • [9] Myocardial Infarct Size by CMR in Clinical Cardioprotection Studies Insights From Randomized Controlled Trials
    Bulluck, Heerajnarain
    Hammond-Haley, Matthew
    Weinmann, Shane
    Martinez-Macias, Roberto
    Hausenloy, Derek J.
    [J]. JACC-CARDIOVASCULAR IMAGING, 2017, 10 (03) : 230 - 240
  • [10] Campbell G, STAT MED